Sign in
Taking peoplePhase 4

The Use of Sublingual Melatonin Premedication in Geriatric Cataract Surgery

Key facts

Who runs it
Al-Azhar University
Where
Egypt and Iraq2 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
60 people, planned
Started
1 Sept 2025
Planned end
15 Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sublingual Melatonin
  • Sublingual Placebo
Record updated
7 January 2026

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • • Age ≥ 60 years; American Society of Anesthesiologists (ASA) physical status I-III; Scheduled for unilateral cataract surgery under local anesthesia; Ability to understand and complete study-related questionnaires

Who cannot take part

  • • Known allergy or hypersensitivity to melatonin; Chronic use of sedatives, hypnotics, or anxiolytics; History of sleep disorders or psychiatric illness; Visual or hearing impairment that would hinder communication; Emergency surgery or anticipated intraoperative complications

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Cataract surgery anesthesia

This trial is currently available in Iraq.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cataract surgery is routinely performed with anesthesia care, whereas anesthesia care for other elective, low-risk, outpatient procedures is applied more selectively. We hypothesize that sublingual melatonin will provide superior anxiolysis and sedation while maintaining a high safety profile and minimizing hemodynamic disturbances.

The 2 groups in the trial

  • Melatonin GroupExisting treatment, for comparison

    a 6 mg sublingual tablet of melatonin will be administered for all patients at 60 minutes before surgery.

    Treatment: Sublingual Melatonin

  • Placebo GroupPlacebo, for comparison

    the participants will be received a visually identical tablet containing inert ingredients at 60 minutes before surgery.

    Treatment: Sublingual Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07036367, who can take part
Record updated
7 January 2026